PMID- 31759831
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20211204
IS  - 1938-0682 (Electronic)
IS  - 1558-7673 (Linking)
VI  - 18
IP  - 1
DP  - 2020 Feb
TI  - Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive 
      Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 
      3-Year Follow-up.
PG  - e46-e54
LID - S1558-7673(19)30280-0 [pii]
LID - 10.1016/j.clgc.2019.09.011 [doi]
AB  - BACKGROUND: There has been no established clinical evidence for using sequential 
      treatment in castration-resistant prostate cancer (CRPC). Despite evident 
      cross-resistance, androgen receptor axis-targeted agents (ARTAs), namely 
      abiraterone (ABI) and enzalutamide (ENZ), are often used sequentially owing to 
      less toxicity compared with chemotherapy. PATIENTS AND METHODS: A multicenter 
      retrospective review of chemotherapy-naive patients with CRPC who had received 
      ABI followed by ENZ (ABI-to-ENZ) or ENZ followed by ABI (ENZ-to-ABI) was 
      conducted. Combined progression-free survival (PFS), overall survival (OS), and 
      prostate-specific antigen (PSA) response (>/= 50% PSA decline) to each drug were 
      compared between the 2 groups at the median follow-up of 36.0 months. RESULTS: 
      There were no significant differences in combined PFS (12.4 vs. 10.9 months; 
      hazard ratio [HR], 0.94; 95% confidence interval [CI], 0.72-1.23; P = .6594) or 
      OS (28.3 vs 29.3 months; HR, 0.96; 95% CI, 0.66-1.38; P = .8314) between the 
      ABI-to-ENZ and ENZ-to-ABI groups. PSA response rate was not significantly 
      different in first-line ARTAs (48.9% vs. 58.4%; P = .153) but significantly 
      higher in ENZ as a second-line ARTA (40.4% vs. 13.7%; P < .0001). Although 
      multivariate analysis revealed that the ABI-to-ENZ sequence was associated with 
      favorable PFS on second-line ARTA (HR, 0.65; 95% CI, 0.49-0.85; P = .0019), it 
      was not associated with an increased combined PFS or OS. CONCLUSION: With 
      relatively longer follow-up, ARTA sequence did not affect clinical outcomes of 
      CRPC treatment except for PSA response and PFS on a second-line ARTA. These 
      findings will be useful information in clinical decision-making, particularly in 
      chemotherapy-unfit patients with CRPC.
CI  - Copyright (c) 2019. Published by Elsevier Inc.
FAU - Kobayashi, Takashi
AU  - Kobayashi T
AD  - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan.
FAU - Terada, Naoki
AU  - Terada N
AD  - Department of Urology, Miyazaki University, Miyazaki, Japan.
FAU - Kimura, Takahiro
AU  - Kimura T
AD  - Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Matsubara, Nobuaki
AU  - Matsubara N
AD  - Department of Breast and Medical Oncology, National Cancer Center Hospital East, 
      Chiba, Japan.
FAU - Murakami, Kaoru
AU  - Murakami K
AD  - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan.
FAU - Mori, Keiichiro
AU  - Mori K
AD  - Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
FAU - Fujimoto, Yumi
AU  - Fujimoto Y
AD  - Department of Breast and Medical Oncology, National Cancer Center Hospital East, 
      Chiba, Japan.
FAU - Akamatsu, Shusuke
AU  - Akamatsu S
AD  - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan.
FAU - Inoue, Takahiro
AU  - Inoue T
AD  - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan.
FAU - Ogawa, Osamu
AU  - Ogawa O
AD  - Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, 
      Japan. Electronic address: ogawao@kuhp.kuoyo-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20190926
PL  - United States
TA  - Clin Genitourin Cancer
JT  - Clinical genitourinary cancer
JID - 101260955
RN  - 0 (AR protein, human)
RN  - 0 (Androgen Receptor Antagonists)
RN  - 0 (Anilides)
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Benzamides)
RN  - 0 (Nitriles)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Tosyl Compounds)
RN  - 2010-15-3 (Phenylthiohydantoin)
RN  - 76W6J0943E (Flutamide)
RN  - 93T0T9GKNU (enzalutamide)
RN  - A0Z3NAU9DP (bicalutamide)
RN  - EC 3.4.21.- (KLK3 protein, human)
RN  - EC 3.4.21.- (Kallikreins)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
RN  - EM5OCB9YJ6 (Abiraterone Acetate)
SB  - IM
MH  - Abiraterone Acetate/administration & dosage
MH  - Aged
MH  - Aged, 80 and over
MH  - Androgen Receptor Antagonists/*administration & dosage
MH  - Anilides/administration & dosage
MH  - Antineoplastic Agents, Hormonal/*administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Benzamides
MH  - Flutamide/administration & dosage
MH  - Follow-Up Studies
MH  - Humans
MH  - Kallikreins/blood
MH  - Male
MH  - Middle Aged
MH  - Nitriles/administration & dosage
MH  - Phenylthiohydantoin/administration & dosage/analogs & derivatives
MH  - Progression-Free Survival
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Neoplasms, Castration-Resistant/blood/*drug therapy/mortality/pathology
MH  - Receptors, Androgen/metabolism
MH  - Tosyl Compounds/administration & dosage
OTO - NOTNLM
OT  - CRPC
OT  - Overall survival
OT  - Progression-free survival
OT  - Second generation antiandrogens
OT  - Sequential treatment
EDAT- 2019/11/25 06:00
MHDA- 2021/01/30 06:00
CRDT- 2019/11/25 06:00
PHST- 2019/05/27 00:00 [received]
PHST- 2019/08/15 00:00 [revised]
PHST- 2019/09/10 00:00 [accepted]
PHST- 2019/11/25 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
PHST- 2019/11/25 06:00 [entrez]
AID - S1558-7673(19)30280-0 [pii]
AID - 10.1016/j.clgc.2019.09.011 [doi]
PST - ppublish
SO  - Clin Genitourin Cancer. 2020 Feb;18(1):e46-e54. doi: 10.1016/j.clgc.2019.09.011. 
      Epub 2019 Sep 26.